2-Deoxy-L-ribose

We are 2-Deoxy-L-ribose CAS:18546-37-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 2-Deoxy-L-ribose
CAS.NO:18546-37-7
Synonyms:
2-deoxy-L-erythro-pentose
L-erythro-2-deoxy-pentose
L-2-deoxyribose
(3R,4S)-3,4,5-Trihydroxypentanal
L-erythro-3,4,5-Trihydroxy-valeraldehyd
L-erythro-2-Desoxy-pentose
2-deoxy-L-ribose
L-erythro-Pentose,2-deoxy
L-threo-2-deoxy-pentose
L-ERYTHRO-PENTOFURANOSE

Molecular Formula:C5H10O4
Molecular Weight:134.13000

Physical and Chemical Properties:
Density: 1.516 g / cm3
Boiling point: 332.1ºC at 760 mmHg
Melting point: 69-72 ° C
Flash point: 154.6ºC
Refractive index: 1.5

Specification:
Appearance: White or yellowish crystalline powder
Purity:≥95%
Water:≤1.0%
Ethanol:≤5.0%
Formamide:≤3.0%
Heavy metal:≤0.002%
Sulphated ash:≤0.1%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Storage Condition:2-8ºC.Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Telbivudine CAS:3424-98-4

Related News: Domestic API companies cooperate with major international companies through commissioned processing, patent transfer, and joint venture production.terc-butil (S) – [1- (aminooxi) propan-2-il] carbamato CAS:953773-59-6 ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.369-34-6 The first is the API – which is the central ingredient.2-fluoro-4-metil-5-nitropiridina CAS:19346-47-5 Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.